Search

OXFORD REGENERATIVE MEDICINE SPINOUT BRINGS ON GLAXOSMITHKLINE DRUG HUNTER AS CSO

The University of Oxford's regenerative drug discovery spinout OxStem Limited has appointed Georg Terstappen as chief scientific officer,...

Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
 
 
 
Bio Roundup: An Alzheimer's Head-Scratcher, OUTBio, GSK & Gilead Shakeups  

BIO ROUNDUP: AN ALZHEIMER'S HEAD-SCRATCHER, OUTBIO, GSK & GILEAD SHAKEUPS  

The devil is in the details, and key clinical trial results made that abundantly clear this week. Eisai and partner Biogen released...

Here's the email 23andMe sent its customers after GSK bought a $300 million stake in the company

HERE'S THE EMAIL 23ANDME SENT ITS CUSTOMERS AFTER GSK BOUGHT A $300 MILLION STAKE IN THE COMPANY

Kimberly White/Getty 23andMe on Wednesday announced a partnership with pharma giant GlaxoSmithKline to develop new treatments for diseases...

 
 
 
Why GSK just made a $300 million bet on 23andMe's approach to finding new medicines

WHY GSK JUST MADE A $300 MILLION BET ON 23ANDME'S APPROACH TO FINDING NEW MEDICINES

Getty Images/Kimberly White Consumer genetics company 23andMe is teaming up with UK drug giant GlaxoSmithKline to develop new drugs. As...

FDA ADCOMM BACKS GLAXOSMITHKLINE'S ONE-SHOT P. VIVAX MALARIA THERAPY

GlaxoSmithKline is close to ending a six-decade drought in relapse-preventing therapies for Plasmodium vivax-one of the most common...

 
 
 
 
 
 

ASCO: ADAPTIMMUNE BUILDS CASE FOR GLAXOSMITHKLINE-PARTNERED T-CELL THERAPY

Adaptimmune has presented updated clinical data on its T-cell therapies. The latest readouts link the GlaxoSmithKline-partnered NY-ESO...

 
 
 
Propeller Health Raises $20M to Move Beyond Respiratory Disease

PROPELLER HEALTH RAISES $20M TO MOVE BEYOND RESPIRATORY DISEASE

Since launching in 2010, Propeller Health has kept its focus on developing connected devices and complementary software for patients...

 
 
 

GALECTO BRINGS ON GSK'S FIBROSIS LEAD AS CMO

Galecto Biotech has hired Richard Marshall, M.D., a medicines development leader at GlaxoSmithKline, to be its new chief medical officer...

 
 
 
As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal

AS NOVARTIS BUYS IN TO GENE THERAPY, GSK BOWS OUT WITH ORCHARD DEAL

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn't yet seen commercial success. In...

DERMAVANT HIRES CSO FROM GLAXOSMITHKLINE, BUYS IN EXCESSIVE SWEATING DRUG

Dermavant Sciences has lured David Rubenstein, M.D., Ph.D., away from GlaxoSmithKline to serve as its CSO. The Roivant company unveiled...

 
 
 
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

GSK announces ‘strategic review' of consumer nutrition portfolio to help fund €13bn Novartis deal

GSK ANNOUNCES ‘STRATEGIC REVIEW' OF CONSUMER NUTRITION PORTFOLIO TO HELP FUND €13BN NOVARTIS DEAL

GlaxoSmithKline could look to sell some â or all â of its nutrition portfolio to help fund the â10.5 billion acquisition of Novartisâ...